Humanigen Inc (HGENQ)

[cowtown jay]

I hope to see two game-changing announcements from Humanigen this week, or in the near term. One announcement may be in regards to further utilizing our notice of patent allowance for the enhancement of CAR-T immunotherapy.

https://www.pennystockdream.com/blog/hgen-up-3217-after-hours-after-receiving-notice-of-allowance-for-patent-application

I actually think that Gracell and Mayo Clinic are already benefitting from this CAR-T enhancement, and I hope that Sanofi will bring this to market not only for their platforms, but for our partner, the South Australian Health and Medical Research Institute ("SAHMRI"), also.

""Expansion of the PREACH-M study is a critical next step in our realignment strategy. Associate Professor Thomas is a world expert in CMML and program leader for Blood Cancers at SAHMRI. SAHMRI is a leader in precision medicine that assists patients in finding the proper treatment for their cancer," commented Cameron Durrant, Chairman and CEO of Humanigen. "Lenzilumab was discovered in Australia, so it is only fitting that we leverage the wealth of local knowledge that exists for lenzilumab as we continue clinical development."

https://ir.humanigen.com/English/news/news-details/2022/Humanigen-and-SAHMRI-Announce-Expansion-of-the-PREACH-M-Study-of-Lenzilumab-in-CMML/default.aspx

The second announcement I'm looking forward to will be after the Novavax stockholder meeting on the 13th, which coincides with our bankruptcy hearing detailing the expanded Milestone Event triggers and payments.